According to Visiongain, GlaxoSmithKline vaccines, such as Infanrix/Pediarix, are in position to achieve high growth rates in emerging markets where vaccination rates are growing rapidly. The market for pediatric combination vaccines is currently dominated by GlaxoSmithKline and Sanofi Pasteur. GlaxoSmithKline’s Infanrix and Pediarix face strong competition from Sanofi’s Pentacel, Pediacel, Repevax and Tetravac. Even so, Visiongain believes GlaxoSmithKline vaccines will be able to hold off the competition from Sanofi and others as they move forward in the new emerging markets. The report estimates that sales for Infanrix will reach $1565 and a compound annual growth rate (CAGR) of 6.7% through 2015. Sales will rise at a CAGR of 5.6% to $2065m by the end of the forecast period in 2021.

PRZOOM / PRTODAY - Newswire Today disclaims any content contained in this article. If you need/wish to contact the company who published the current release, you will need to contact them - NOT us. Issuers of articles are solely responsible for the accuracy of their content. Our complete disclaimer appears here.IMPORTANT INFORMATION: Issuance, publication or distribution of this press release in certain jurisdictions could be subject to restrictions. The recipient of this press release is responsible for using this press release and the information herein in accordance with the applicable rules and regulations in the particular jurisdiction. This press release does not constitute an offer or an offering to acquire or subscribe for any Global Information, Inc. securities in any jurisdiction including any other companies listed or named in this release.